Safety of anacetrapib in patients with or at high risk for coronary heart disease.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  New England Journal of Medicine

• Publication date

  2010-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1009744PMID 21082868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

  2010cited by this paper
• Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib

  2010cited by this paper
• Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

  2009cited by this paper
• Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community

  2009cited by this paper
• Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

  2009cited by this paper
• Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.

  2008cited by this paper
• Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.

  2008cited by this paper
• Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

  2008cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

  2007cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

  2005cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper

• Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol

  2026influential citation
• Cholesteryl Ester Transfer Protein Inhibitors: State of the Science

  2026cites this paper
• Cholesterol: an ancient ally or modern menace?

  2026cites this paper
• Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?

  2026cites this paper
• Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study

  2025cites this paper
• A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

  2025cites this paper
• ASSESSMENT OF CARDIOVASCULAR MARKERS AND RISK-FACTORS AMONG NEWLY DIAGNOSED HYPERTENSIVE PATIENTS IN BENIN CITY

  2025cites this paper
• A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

  2025cites this paper
• Phospholipids that plug the pores of cholesteryl ester transfer protein control its lipid transfer dynamics

  2025cites this paper
• Genetic determinants of lipid metabolism in cardioprotection: From mechanisms to clinical practice

  2025cites this paper
• Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials

  2025cites this paper
• Comparative transcriptome and methylome of polar bears, giant and red pandas reveal diet‐driven adaptive evolution

  2024cites this paper
• Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia.

  2024cites this paper
• Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?

  2024cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

  2024cites this paper
• Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases

  2024cites this paper
• Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors.

  2024cites this paper
• Impact of Elevated Lipoprotein A on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

  2024cites this paper
• Novel Therapeutic Approaches for the Management of Elevated Lipoprotein(a): From Traditional Agents to Future Treatment Options

  2024cites this paper
• Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review

  2024cites this paper
• High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review

  2024cites this paper
• Voluntary exercise fails to prevent metabolic dysfunction‐associated steatotic liver disease progression in male rats fed a high‐fat high‐cholesterol diet

  2024cites this paper
• Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia

  2023cites this paper
• HDL as a Treatment Target: Should We Abandon This Idea?

  2023cites this paper
• Why and when should be lipoprotein(a) level measured?

  2023cites this paper
• Structure-based mechanism and inhibition of cholesteryl ester transfer protein

  2023cites this paper
• Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis

  2023cites this paper
• Association of the polymorphisms of the cholesteryl ester transfer protein gene with coronary artery disease: a meta-analysis

  2023cites this paper
• Integrating multiple traits for improving polygenic risk prediction in disease and pharmacogenomics GWAS

  2023cites this paper
• Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis

  2023cites this paper
• High-density lipoprotein cholesterol and clinical outcomes in diabetes mellitus.

  2023cites this paper
• Lipoprotein(a): cardiovascular risk and emerging therapies

  2023cites this paper
• Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

  2023cites this paper
• Can we revive CETP-inhibitors for the prevention of cardiovascular disease?

  2022cites this paper
• Recent lipoprotein(a) trials

  2022cites this paper
• The Inherited Hypercholesterolemias.

  2022cites this paper
• CETP Inhibitors: Should We Continue to Pursue This Pathway?

  2022cites this paper
• High-density lipoprotein cholesterol efflux capacity and incidence of coronary artery disease and cardiovascular mortality: a systematic review and meta-analysis

  2022cites this paper
• The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis

  2022cites this paper
• Association of High-Density Lipoprotein Cholesterol Phenotypes with the Risk of Cardiovascular Diseases and Mortality: A Cohort Study in Korea

  2022cites this paper
• Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease

  2022cites this paper
• Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.

  2022cites this paper
• Relationship Between Lipid Profiles and Hypertension: A Cross-Sectional Study of 62,957 Chinese Adult Males

  2022cites this paper
• Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

  2022cites this paper
• High-density lipoprotein: a double-edged sword in cardiovascular physiology and pathophysiology

  2021cites this paper
• Study of effect modifiers of genetically predicted CETP reduction

  2021cites this paper
• Biomarker Discovery in Atherosclerotic Diseases Using Quantitative Nuclear Magnetic Resonance Metabolomics

  2021cites this paper
• Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.

  2021cites this paper
• Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention.

  2021cites this paper
• The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies.

  2021cites this paper
• Inherited Variants in SCARB1 Cause Severe Early-Onset Coronary Artery Disease

  2021cites this paper
• The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines

  2021cites this paper
• Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications

  2021influential citation
• High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events

  2021cites this paper
• Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study

  2021cites this paper
• Lipoprotein (a): When to Measure and How to Treat?

  2021cites this paper
• Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

  2021cites this paper
• Drug discovery and development: An overview of modern methods and principles

  2021cites this paper
• Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy

  2021cites this paper
• Thematic Lipid Transfer Proteins Cholesteryl ester transfer protein and its inhibitors

  2020cites this paper
• Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

  2020cites this paper
• The Role of CETP Modulation and Inhibition in the Progression of Coronary Heart Disease

  2020cites this paper
• Lipoprotein (a): Principles from Bench to Bedside

  2020cites this paper
• Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels—Brief Report

  2020cites this paper
• Cholesteryl ester transfer protein inhibitors in precision medicine.

  2020cites this paper
• Prognostic Value of Admission Mean Corpuscular Volume for Major Adverse Cardiovascular Events following Stent Implantation in Nondiabetic and Diabetic Patients with Acute Coronary Syndrome

  2020cites this paper
• The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men.

  2020cites this paper
• High-Density Lipoproteins and Cardiovascular Disease

  2020cites this paper
• 2D QSAR studies on a series of (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one as CETP inhibitors

  2020cites this paper
• ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: a rodent model rescued from neonatal death.

  2020cites this paper
• Lipid efflux mechanisms, relation to disease and potential therapeutic aspects.

  2020cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2020cites this paper
• The mystery of evacetrapib - why are CETP inhibitors failing?

  2020cites this paper
• Theory and practical use of Bayesian methods in interpreting clinical trial data: a narrative review.

  2020cites this paper
• Serum Levels of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), and Cardiac Function in Patients with Unstable Angina Pectoris

  2020cites this paper
• Lipoprotein(a) and Cardiovascular Diseases　- Revisited.

  2020cites this paper
• Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials

  2020cites this paper
• Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule

  2020cites this paper
• Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?

  2020cites this paper
• Lipid Disorders and Familial Hypercholesterolaemia

  2019cites this paper
• Emerging Lipid-Lowering Therapies in Secondary Prevention

  2019cites this paper
• THE ROLE OF HYPERCHOLESTEROLEMIA IN POPULATION MORBIDITY NOSOLOGICAL STRUCTURE DEVELOPMENT

  2019cites this paper
• Antisense Oligonucleotides Targeting Lipoprotein(a)

  2019cites this paper
• Hypolipidemic Therapy and Chronic Kidney Disease: Effects on Cardiovascular Risks and Renal Dysfunction

  2019cites this paper
• Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction.

  2019cites this paper
• Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis

  2019cites this paper
• Molecular Nutrition Fats

  2019cites this paper
• Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?

  2019cites this paper
• Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events

  2019cites this paper
• Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.

  2019cites this paper
• New Frontiers in Lp(a)-Targeted Therapies.

  2019cites this paper
• Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case

  2019cites this paper
• HEART UK consensus statement on Lipoprotein(a): A call to action.

  2019cites this paper
• Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?

  2019cites this paper
• Assessing the structure-function relationships of the apolipoprotein(a) kringle IV sub-type 10 domain

  2019cites this paper
• Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China

  2019cites this paper
• Medication Errors.

  2019cites this paper
• Effect of Food on the Pharmacokinetics of 2 Formulations of DRL‐17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males

  2019cites this paper
• Enhancement of HDL by Policosanol

  2019cites this paper
• Therapeutic management of hyperlipoproteinemia (a)

  2019cites this paper